The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 14, 2020

Filed:

Dec. 09, 2016
Applicant:

Universitätsklinikum Jena, Jena, DE;

Inventors:

Michael Kiehntopf, Jena, DE;

Diana Schmerler, Jena, DE;

Thomas Deufel, Jena, DE;

Frank Brunkhorst, Jena, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/53 (2006.01); G01N 33/68 (2006.01); C07K 14/81 (2006.01); G06F 19/00 (2018.01); G16H 50/30 (2018.01); C07K 16/38 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); C07K 14/8125 (2013.01); C07K 16/38 (2013.01); G01N 33/5308 (2013.01); G01N 33/6848 (2013.01); G06F 19/00 (2013.01); G16H 50/30 (2018.01); C07K 2317/34 (2013.01); G01N 2333/8125 (2013.01); G01N 2570/00 (2013.01); G01N 2800/26 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01);
Abstract

The present invention relates a method for the diagnosis, prediction or risk stratification for mortality and/or disease outcome of a subject that has or is suspected to have sepsis, comprising determining the presence and/or level of antitrypsin (ATT) or fragments thereof in a sample taken from said subject and/or determining the presence and/or level of transthyretin (TTR) or fragments thereof, wherein the presence and/or level of ATT and/or TTR or fragments thereof is correlated with an increased risk of mortality and, wherein said increased risk of mortality and/or poor disease outcome is given if the level of ATT is below a certain cut-off value and/or the level of fragments thereof is above a certain cut-off value and/or said increased risk of mortality and/or poor disease outcome is given if the level of TTR is below a certain cut-off value and/or the level of fragments thereof is below a certain cut-off value. The invention relates in general to the use of ATT and/or TTR or its fragments for the diagnosis of sepsis, and to nucleotides of SEQ ID NO. 2 to 14.


Find Patent Forward Citations

Loading…